Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Neoplasms by Site 1Neoplasms 1Lung Neoplasms 1Lung Diseases 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

Carboplatin 9Pemetrexed 6Erlotinib Hydrochloride 5pembrolizumab 3osimertinib 3durvalumab 3camrelizumab 3Gemcitabine 3Gefitinib 3Cisplatin 3selpercatinib 2pralsetinib 2apatinib 2Radiosurgery 2taletrectinib 1sotorasib 1sintilimab 1repotrectinib 1patritumab 1necitumumab 1ficlatuzumab 1exemestane 1entinostat 1cobimetinib 1ceralasertib 1alectinib 1Vinorelbine 1Tyrosine Kinase Inhibitors 1Telescopes 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Respiratory Tract Diseases × exemestane × Thoracic × Clear all
NCT01594398 2021-11-19

ENCORE110

Syndax Pharmaceuticals

Phase 1 Completed
14 enrolled
BreastThoracic

Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡